CMPX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Compass Therapeutics Inc. (CMPX) is not a strong buy at the moment for a beginner investor with a long-term horizon. While the company has promising future catalysts, such as potential FDA filings and a commercial launch in 2027, the current financial performance, technical indicators, and lack of immediate positive trading signals suggest holding off on investment for now.
The MACD histogram is negative at -0.103, indicating bearish momentum. RSI is at 29.372, which is close to oversold territory but still neutral. Moving averages are converging, showing no clear trend. The stock is trading near its support level of 5.42, but the overall technical indicators do not suggest a strong buy signal.
Analysts have initiated coverage with Buy ratings and high price targets ($13-$15), citing the potential of the company's lead asset, Tovecimig, in treating biliary tract cancer.
Significant upside potential in the early-stage pipeline.
Hedge funds like Palo Alto Investors LP have recently acquired shares, indicating institutional confidence.
The company reported a net loss of $66.5 million in 2025/Q4, with no revenue growth and declining gross margins.
Technical indicators suggest bearish momentum.
No recent congress trading data or influential political activity to support sentiment.
In Q4 2025, the company reported a net loss of $15.72 million, an EPS of -$0.09 (down 18.18% YoY), and no revenue growth. Gross margin dropped to 0, indicating poor financial health.
Analysts are optimistic about the company's future, with Buy ratings and price targets ranging from $13 to $15. They highlight the potential of Tovecimig and the company's pipeline, but near-term financial struggles and lack of immediate catalysts temper the enthusiasm.
